Brazil's health regulatory agency, Anvisa, suspended and ordered the recall of a specific lot of paracetamol on July 30, 2026 [3].
This action is critical because the contaminated medication poses a direct health risk to consumers who may ingest mold-affected tablets. The presence of fungi in pharmaceutical products can lead to adverse reactions, or compromise the efficacy of the drug.
The agency identified signs of mold in tablets of Paramol 750 mg [2]. Consequently, Anvisa determined that lot 114053 [1] must be removed from the market and collected from pharmacies and distributors across the country.
Officials said the decision followed the identification of tablets showing clear signs of contamination. The recall is a precautionary measure to ensure public safety and maintain the quality standards of medications distributed within Brazil.
Consumers are advised to check their medication packaging for the specified lot number. Those in possession of the affected batch should stop using the product immediately and contact the manufacturer or the health agency for guidance.
Anvisa continues to monitor pharmaceutical batches to prevent the distribution of compromised medicines. The agency said the national alert aims to mitigate any potential harm to patients using the 750 mg dosage of the analgesic [2].
“Anvisa suspended and ordered the recall of a specific lot of paracetamol.”
This recall highlights the vulnerabilities in pharmaceutical storage and quality control chains. When a common over-the-counter analgesic like paracetamol shows signs of mold, it suggests a failure in moisture control or sealing during the manufacturing or distribution process, prompting stricter oversight of batch integrity by national regulators.
